Skip to content

Bburgdor25kdabfldqlib

Published: August 9, 2026Updated: August 15, 2026

This test detects antibodies against the 25kD protein of Borrelia burgdorferi, the bacterium that causes Lyme disease, using an immunoblot technique.

Quick summary

{"The test checks for antibodies to a specific 25kD protein (OspC) of the Lyme disease bacterium","It is typically used after a positive or equivocal ELISA screening test","A positive result indicates exposure to the Lyme disease bacterium","The 25kD band is particularly important for detecting early infection","Results should be interpreted together with clinical symptoms and exposure history"}

Medically reviewed by WellAlly Editorial TeamLast reviewed August 15, 2026Editorial policy

Key facts at a glance

LOINC
12888-4
Short code
B25KIB
Synonyms
B burgdor25kD Ab Fld Ql IB
Category
chemistry
Sample
serum
Container
Sterile, leak-proof plastic collection tube (red-top or serum separator tube)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
Immunoblot (Western blot) for detection of IgG antibodies against the 25 kDa outer surface protein (OspC or related) of Borrelia burgdorferi
CPT
86617
SNOMED
397662009
Specimen volume
1-2 mL serum
Stability
Stable at room temperature for 8 hours; refrigerated (2-8°C) for 7 days; frozen (-20°C or below) for 30 days. Avoid repeated freeze-thaw cycles.
Hemolysis max
100
Lipemia max
100
Icterus max
50
TAT
24–72 hours
Order
routine

What is this test?

The Borrelia burgdorferi 25kD Antibody Immunoblot test is a specialized blood test that detects antibodies specifically targeting the 25kD protein (known as OspC or Outer Surface Protein C) of the bacteria that cause Lyme disease. Unlike simple screening tests, the immunoblot (also called Western Blot) can identify antibodies to individual bacterial proteins, providing more detailed information about your immune response.

Why is the 25kD protein important?

The 25kD protein (OspC) is one of the first antigens (substances that trigger immune response) produced by Borrelia burgdorferi during early infection. This makes the 25kD antibody test particularly valuable for detecting recent or early-stage Lyme disease, when other tests may still be negative. The presence of antibodies to this specific protein helps confirm that your immune system has responded to the Lyme disease bacterium.

How is the test performed?

A blood sample is drawn from a vein in your arm. In the laboratory, the sample is tested using immunoblot technique, which separates the bacterial proteins by size and then detects whether your blood contains antibodies that bind to the 25kD protein. Results are typically reported as 'positive' or 'negative' for the presence of antibodies to this specific protein.

What do the results mean?

A positive result means antibodies to the 25kD protein were detected in your blood, suggesting you have been exposed to the Lyme disease bacterium. A negative result means no antibodies to this protein were found. However, it is important to understand that this is just one part of Lyme disease testing—results should always be interpreted by your healthcare provider along with your symptoms, exposure history, and other test results.

Reference range

Negative: No reactive bands detected at 25 kDa position. Equivocal: Indeterminate reactivity requiring clinical correlation. Positive: Distinct reactive band present at 25 kDa indicating presence of specific antibodies. Results should be interpreted as part of a complete Lyme disease serologic panel.N/A

Specimen: serum

No special preparation required. Patient should inform clinician of any antibiotic use, recent tick exposure, travel history to endemic areas, and current symptoms (erythema migrans, arthritis, neurological symptoms).

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

◆Associated findings1

Frequently asked questions

Do I need to fast before this test?
No, fasting is not required for this blood test. You can eat and drink normally before the test.
How long does it take to get results?
Results are typically available within 3-7 days, as the immunoblot test requires specialized laboratory processing.
Can this test tell me if I have active Lyme disease?
No, this test detects antibodies, which indicate exposure to the bacterium, but cannot distinguish between past treated infection, current active infection, or sometimes even cross-reactions with other conditions. Your healthcare provider will interpret the result in context of your symptoms and clinical history.
Why was this test ordered after my ELISA test?
The immunoblot is typically used as a confirmatory test. If your initial ELISA screening test was positive or equivocal, the immunoblot provides more detailed information about your antibody response to specific Lyme disease proteins, helping to confirm or rule out the diagnosis.
Can the test be positive if I was vaccinated against Lyme disease?
There is currently no widely available human Lyme disease vaccine in the United States. Previous vaccination attempts (like LYMErix) were discontinued, so vaccination is not a common cause of positive results. However, some other bacterial infections may cause cross-reactions.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 15, 2026. · Read our editorial policy